Welcome
Support Centre
12 May 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

Submit your study protocol
[ Print-friendly version ]
Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day)
ISRCTN ISRCTN38094599
ClinicalTrials.gov identifier
Public title Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day)
Scientific title
Acronym N/A
Serial number at source CL3-20098-050
Study hypothesis To assess the efficacy of agomelatine in the prevention of relapse in non-depressed out-patients with Generalized Anxiety Disorder (GAD) after an initial response to agomelatine.
Ethics approval First ethics committee approval in Estonia (Tallin Medical Research Ethics Committee) on 16 August 2007 (ref: 1121)
Study design Randomised, double-blind, parallel group, placebo-controlled, multi-centre, phase III study.
Countries of recruitment Canada, Europe.
Disease/condition/study domain Generalized anxiety disorder
Participants - inclusion criteria 1. Aged over 18 years
2. Out-patients of both genders
3. Fulfilling the Diagnostic and Statistical Manual of mental disorders fourth edition (DSM-IV) criteria for GAD
Participants - exclusion criteria 1. Women of childbearing potential without effective contraception
2. Patients meeting DSM-IV-TR current diagnosis of psychiatric disorder other than GAD
3. Any clinically relevant abnormality detected during the physical examination, ECG or laboratory tests likely to interfere with the study conduct or evaluations
Anticipated start date 15/10/2007
Anticipated end date 15/03/2010
Status of trial Ongoing
Patient information material
Target number of participants 370
Interventions Agomelatine versus placebo
Primary outcome measure(s) Time to relapse
Secondary outcome measure(s) 1. Evaluation of anxiety (Hamilton rating scale for anxiety [HAM-A])
2. Safety
Sources of funding Institut de Recherches Internationales Servier (France)
Trial website
Publications
Contact name Prof  Istvan  Bitter
  Address Department of Psychiatry and Psychotherapy
Semmelweis University
Balassa u.6.
  City/town Budapest
  Zip/Postcode 1083
  Country Hungary
Sponsor Institut de Recherches Internationales Servier (France)
  Address 6, Place des Pléiades
  City/town Courbevoie
  Zip/Postcode 92415
  Country France
Date applied 24/09/2007
Last edited 26/03/2008
Date ISRCTN assigned 26/03/2008
News
28 Sept 2007: 2007 Update of NHS Trusts Clinical Trials Register now available online
Aug 2007: Searches on ISRCTN register can now be bookmarked
Jul 2007: Patient information material field added to the ISRCTN Register
May 2007: WHO launches the International Clinical Trials Registry Search Portal
3 Apr 2007: Q&As regarding trial registration in the UK
4 Dec 2006: Trials taking place in the UK collated in 'Gateway'

© ISRCTN


BioMed Central